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Abstract
AIM: To investigate the antitumor activities of tachyplesin
on human hepatocellular carcinoma (HCC) cells.
METHODS: Tachyplesin, isolated from acid extracts of
Chinese horseshoe crab (Tachypleus tridentatus) hemocytes,
was used to treat the human HCC cell line SMMC-7721. Effects
of tachyplesin on the proliferation of SMMC-7721 cells were
measured with trypan blue dye exclusion test and HE staining.
The morphology and ultrastructure of the cells were examined
by light microscopy and transmission electron microscopy,
respectively. The activities of g-glutamyltransferase (g-GT) and
tyrosine aminotransferase (TAT) were assayed with
biochemical methods. The levels of alpha fetoprotein (a-
FP), proliferating cell nuclear antigen (PCNA), p21WAF1/CIP1
and c-myc were examined by immunocytochemistry.
RESULTS: After treatment with tachyplesin 3.0 mg/L, the
proliferation of SMMC-7721 cells was inhibited significantly,
with the cell growth inhibitory rate amounted to 55.57 % and
the maximum cell mitotic index declined by 43.68 %. The
morphology and ultrastructure underwent restorational
alteration. The activity of g-GT declined while TAT activity
increased obviously, and the levels of a-FP and PCNA decreased.
Moreover, the expression of p21WAF1/CIP1 protein was up-
regulated and that of c-myc protein was down-regulated.
CONCLUSION: Tachyplesin could effectively inhibit the
proliferation of hepatocarcinoma cells, reverse the malignant
morphological and ultrastructural characteristics, alter the
levels of enzymes and antigens, regulate the expression of
differentiation-associated oncogene and tumor suppressor
gene, and induce hepatocarcinama cell differentiation.
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INTRODUCTION
The induction of tumor cell differentiation is a new strategy
of drug therapy of tumors. In recent years, many studies
showed that malignant tumor cells could be induced to
terminal differentiation by some inducers. Differentiation-
inducing therapy has already been applied to leukemias,
lymphomas, and other solid tumors[1]. On the other hand, the
study on antitumor activities of marine bioactive substances
has became an important field in exploiting marine bioactive
substances and antitumor drugs[2-4]. In order to explore the
method and means of regulating the proliferation of tumor
cell and reversing its malignant phenotypes artificially, we
focus on screening and identifying marine bioactive
substances, especially those with low molecular weight which
can adjust cell signal transduction and regulate cell
proliferation and differentiation.
      Horseshoe crab, a kind of marine animal, which has
survived relatively unchanged for the past 350 million years,
now is at the center of a resource tug of war. During the past
two decades, many bioactive substances with special functions,
including clotting factors, lectins, proteinase inhibitors,
defensins, tachyplesin and tachystatins, have been found in
the hemocytes and hemolymph plasma of horseshoe crab[5-9].
In our previous works, we reported that tachyplesin could alter
the malignant morphological and ultrastructural characteristics
and regulate the proliferation and differentiation of human
gastric carcinoma cells[10,11]. In this paper, the antitumor
activities of tachyplesin on hepatocellular carcinoma cell line
SMMC-7721 were investigated to further clarify the antitumor
mechanism of tachyplesin.
MATERIALS AND METHODS
Drugs and reagents
Tachyplesin was isolated from acid extracts of Chinese
horseshoe crab (Tachypleus tridentatus) hemocytes as
described by Nakamura et al[12]. RPMI-1640 medium were
obtained from Gibco. Fetal calf serum was supplied by Si-Ji-
Qing Biotechnology Co. (Hangzhou, China). Trypan blue were
purchased from Sigma Co. g-GT kit was purchased from
Shanghai Lianyang Biotechenical Co. Mouse anti-human a-
FP, PCNA, p21WAF1/CIP1, c-myc monoclonal antibodies were
purchased from Santa Cruz. SP detection kit and DAB kit were
purchased from Beijing Zhongshan Biotechnology Co.
Cell culture and treatment
SMMC-7721 cells, provided by the Institute of Biochemistry
and Cell Biology, Shanghai Institute of Biological Sciences,
Chinese Academy of Sciences, were maintained in RPMI-1640
medium supplemented with 20 % heat-inactivated fetal calf
serum, 100 units/mL penicillin, 100 mg/L streptomycin and
50 mg/L kanamycin at 37 , 5 % CO2 in air atmosphere.
SMMC-7721 cells were treated with culture medium
containing tachyplesin after being seeded for 24 hours.
Statistical analysis
Student’s t test was used to compare the difference between
control group and tachyplesin treatment group. The data of cell
growth, mitotic index and enzymatic activities were presented
as the mean with the corresponding standard deviation. P value
of less than 0.05 is considered statistically significant.
RESULTS
Effects of tachyplesin on the proliferation of SMMC-7721 cells
Under concentration of 2.5, 3.0, 3.5 mg/L, tachyplesin
significantly inhibited the proliferation of SMMC-7721 cells.
The growth inhibitory rates on SMMC-7721 cells on the
seventh day were 47.09 %, 55.57 % and 62.77 %, respectively
(P<0.05) (Figure 1). According to the principle of induced
differentiation treatment, we chose 3.0 mg/L tachyplesin for
induced treatment. Cell mitotic index determination showed
that SMMC-7721 cells had vigorous proliferation capability,
reached to the divided peak on the fourth day, and the
maximum mitotic index amounted to 35.19±2.17 ‰. However
the mitotic index of the cells treated with 3.0 mg/L tachyplesin
was only 19.82±1.89 ‰ at the divided peak, declined by
43.68 % (P<0.05), and the divided peak was on the third day
after tachyplesin treatment (Figure 2).
Figure 1  Effect of tachyplesin on the growth of SMMC-7721 cells
Figure 2  Effect of tachyplesin on the mitotic index of SMMC-
7721 cells
Effects of tachyplesin on the morphology and ultrastructure
of SMMC-7721 cells
SMMC-7721 cells showed typical malignant morphological
and ultrastructural characteristics in SMMC-7721 cells like
other epithelial cancer cells. Under light microscope, the
volume of SMMC-7721 cells was relatively small, nuclei were
www.wjgnet.com
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Determination of cell growth curve and cell mitotic index
SMMC-7721 cells (5×104/mL) were seeded in small culture
flasks or in little penicillin bottles with cover slips respectively.
Tachyplesin treatment was performed after cells being
subcultured for 24 hours. From the first to seventh day, three
flasks of untreated or tachyplesin-treated cells were harvested
every day, and the viable cells were counted by the trypan
blue dye exclusion test. Meanwhile, the cover slips with
untreated or tachyplesin-treated cells were also taken out every
day, fixed in Bouin-Hollande fixative, and stained with
Hematoxylin-Eosin (HE) staining. The mitotic cells in 1000
cells on each cover slip were counted.
Sample preparation for the light microscopy
SMMC-7721 cells and the cells treated with 3.0 mg/L
tachyplesin for 5 days were seeded in little penicillin bottles
with cover slips, and grown in the normal culture medium or
in the medium containing 3.0 mg/L tachyplesin for 48 hours,
respectively. The cells on cover slips were rinsed with D-
Hank’s solution twice at 37 , fixed overnight in Bouin-
Hollande fixative, stained with Hematoxylin-Eosin staining,
and observed under light microscope.
Sample preparation for transmission electron microscopy
SMMC-7721 cells and the cells treated with 3.0 mg/L
tachyplesin for 7 days were rinsed with D-Hank’s solution
twice at 37 , shaved into centrifuge tubes with plastic scraper.
Cells were centrifuged at 2000 rpm for 15 min, and the
supernatants were removed. The precipitates were prefixed in
2.5 % glutaraldehyde for 2 hours and postfixed in 1 % osmian
tetroxide for 2 hours, dehydrated in ethanol series, embedded
in epoxy resin 618, stained with lead citrate and uranyl acetate,
and observed under the JEM-100CX  transmission electron
microscope.
Assays for the activities of g-glutamyltransferase (g-GT) and
tyrosine aminotransferase (TAT)
SMMC-7721 cells and the cells treated with 3.0 mg/L tachyplesin
for 7 days were harvested, counted, and sonicated in ice-cooled
0.1 mol/L PBS. The homogenates were centrifuged and the
supernatants were subjected to assay of enzymatic activities.
The g-GT activity was determined with g-GT reagent kit and
the TAT activity was detected according to the method
described by Marston et al[13]. The activities of g-GT and TAT
were valued as OD unit per 1×106 cells.
Immunocytochemistry analysis
SMMC-7721 cells and the cells treated with 3.0 mg/L
tachyplesin for 5 days were seeded in little penicillin bottles
with cover slips for 48 hours respectively. The cells grown on
cover slips were fixed with cold acetone for 10 min, rinsed
twice in PBS for 15 min. They were then immersed in 3 %
hydrogen peroxide for 10 min, washed with distilled water
and PBS for 15 min, blocked with 10 % normal goat serum for
10 min at room temperature, and incubated with the monoclonal
mouse anti-human a-FP, PCNA, p21WAF1/CIP1, c-myc antibodies
at 4  overnight. After incubation with primary antibodies,
cover slips were rinsed twice in PBS for 15 min, incubated
with biotin-labeled secondary antibody at 37  for 10 min,
rinsed twice in PBS for 15 min, and then incubated in
streptavidin-peroxidase at 37  for 10 min. The antigen-
antibody complex was visualized with diaminobenzidine
(DAB) substrate. Negative controls were incubated in the
absence of primary antibodies.
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large and irregular with several nucleoli in it, and cytoplasm
volume was small (Figure 3A). And it was revealed by
transmission electron microscope that the necleo-cytoplasmic
ratio of SMMC-7721 cells was relatively large, nuclei were
irregular with many heterochromatins and few euchromatins
and large nucleolus in it, while cell organelles were not well-
developed in the cytoplasm (Figure 3C). However, after being
treated with 3.0 mg/L tachyplesin, SMMC-7721 cells had
undergone a significant morphological and ultrastructural
changes and appeared as normal differentiated epithelial cells.
The cells turned to be more spread and flat, the necleo-
cytoplasmic ratio was reduced, the shape of nuclei became
regular, heterchromatin in nucleus decreased while
euchromatin increased, the volume of nucleolus was reduced,
and cytoplasm was abundant with well-developed cell
organelles (Figure 3B,D).
Effects of tachyplesin on the activities of g-GT and TAT in
SMMC-7721 cells
The human hepatocarcinoma SMMC-7721 cells had high g-GT
activity and low TAT activity. After treatment with 3.0 mg/L
tachyplesin, the activity of g-GT in SMMC-7721 cells were
declined from 0.48 0.04 Unit to 0.30 0.02 Unit (P<0.05) while
TAT activity increased from 0.44 0.04 Unit to 0.90 0.04 Unit
(P<0.05) as shown in Figure 4.
Figure 4  Effects of tachyplesin on the activies of g-GT and TAT
in SMMC-7721 cells
Effects of tachyplesin on a-FP, PCNA levels in SMMC-7721 cells
High level of a-FP was detected in the cytoplasm and nucleus
of SMMC-7721 cells (Figure 5A). However, after being treated
with 3.0 mg/L tachyplesin, the cells had a very low level of a-
FP (Figure 5B). The PCNA level was also high and mainly
distributed in the nucleus of SMMC-7721 cells, especially in
the spherical cells, while the immunocytochemical signal was
weak in the tachyplesin-treated cells (Figure 5C,D).
Effects of tachyplesin on protein p21WAF1/CIP1, c-myc levels in
SMMC-7721 cells
To investigate the effects of tachyplesin on the expression of
differentiation-associated tumor suppressor gene and
oncogene, the levels of p21WAF1/CIP1 and c-myc proteins were
also examined. Immunocytochemistry showed that the level
of p21WAF1/CIP1 protein was low in the nucleus and cytoplasm
of the untreated cells while it was very high in the cells treated
with tachyplesin (Figure 5E,F). High level of c-myc was
observed in SMMC-7721 cells and exposure of the cells to
tachyplesin resulted in an obvious decrease of c-myc protein
(Figure 5G,H).
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Figure 3  Effects of tachyplesin on the morphology and ultra-
structure of SMMC-7721 cells. A: SMMC-7721 cells ( 536); B:
SMMC-7721 cells treated with tachyplesin ( 536); C: The
nucleo-cytoplasm ratio is large, the shape of nucleus is irregu-
lar and cell organelles are not well-developed in the cytoplasm
of SMMC-7721 cell ( 8800); D: The nucleo-cytoplasm ratio
decreased, the shape of nucleus is regular and cell organelles
are well-developed in the cytoplasm of tachyplesin-treated
SMMC-7721 cell ( 11000)
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Figure 5  Effects of tachyplesin on the levels of a-FP, PCNA, p21WAF1/CIP1, c-myc proteins in SMMC-7721 cells ( 536).
A: The high level of a-FP in SMMC-7721 cells detected by immunocytochemistry; B: The level of a-FP in the tachyplesin-treated
SMMC-7721 cells is decreased; C: The high level of PCNA in SMMC-7721 cells; D: The level of PCNA in the tachyplesin-treated
SMMC-7721 cells is decreased; E: The low level of p21WAF1/CIP1 in SMMC-7721 cells; F: The level of p21WAF1/CIP1 in the tachyplesin-
treated SMMC-7721 cells is increased; G: The high level of c-myc in SMMC-7721 cells; H: The level of c-myc in the tachyplesin-
treated SMMC-7721 cells is decreased.
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DISCUSSION
It is important to examine the changes of the main malignant
characteristics of cancer cells in order to evaluate the malignant
phenotype reversion. Continual division and constant
proliferation are important characteristics of tumor cells. The
proliferating activity of cells is inversely correlated with the
degree of differentiation. Therefore, inhibiting the proliferation
of tumor cells is a significant index in induction of
differentiation[1,14]. In the present study, the results of the cell
growth curve and mitotic index assay indicated that tachyplesin
could inhibit the multiplicative activity of hepatocarcinoma
cells effectively, with similar effects of growth inhibition as
retinoic acid, HMBA and dimethyl sulphoxide on human
hepatocarcinoma cells HepG2 and SMMC-7721[15-20]. It
suggests that tachyplesin could suppress tumor cell growth as
other differentiation inducers.
     Malignant morphology and ultrastructure are other
important characteristics of tumor cells. Previous studies had
revealed that lots of differentiation inducers could reverse the
morphology and ultrastructure of tumor cells. Therefore,
evaluating the changes of these two characteristics in tumor
cells is important in determining the effects of exotic
substances, especially differentiation inducers on tumor cells.
Our results showed that tachyplesin could reverse the malignant
morphological and ultrastructural characteristics of SMMC-
7721 cells as it did on gastric carcinoma cells or other inducers
on hepatocarcinoma cells and other tumor cells[10,18,19].
      a-FP, an oncofetal antigen, is as an important tumor-
specific marker for the diagnosis of hepatocellular carcinoma
and has been widely used in clinical setting[21-25]. PCNA, the
auxiliary protein of DNA polymerase d, e, plays an important
role in DNA replication, repair and cell cycle control, and can
be used as differentiation marker of hepatocarcinoma[26-30]. The
increased levels of a-FP and PCNA are correlated with
hepatocyte malignancy, and many differentiation inducers such
as HMBA, retinoic acid and sodium butyrate could decrease their
levels in hepatocarcinoma cells[18-20]. g-GT and TAT also can be
used as tumor markers of hepatocellular carcinomaIn[31-33]. The
decreased activity of TAT and the increased levels of a-FP,
PCNA and g-GT activities are correlated with hepatocyte
malignancy. Many differentiation inducers, such as retinoic
acid and HMBA, could reduce the levels of a-FP and PCNA
and g-GT while increase the level of TAT in hepatocarcinoma
cells[18,19,34]. Our results revealed that the levels of a-FP and
PCNA and g-GT were down-regulated and the activity of TAT
was increased in the tachyplesin-treated cells, indicating that
tachyplesin could alter the activities of differentiation-
associated enzymes and decrease the levels of tumor-associated
antigens as many differentiation inducers.
      In addition, many tumor suppressor genes and oncogenes,
which were correlative with the tumorigenesis and progression
and prognosis of hepatocarcinoma, also could serve as index
of induced differentiation. p21WAF1/CIP1, the pioneer member of
p21 family of cyclin-cdk inhibitor class of proteins, has been
implicated as a growth arrest mediator in cell terminal
differentiation and apoptosis[1,30,35]. Many inducers such as
sodium butyrate could increase the expression of p21WAF1/CIP1
of hepatocarcinoma cells[20]. In the meantime, c-myc gene also
plays an essential role in cell proliferation, differentiation, and
apoptosis[36,37]. Down-regulation of c-myc expression induced
by differentiation signals is regarded as a hallmark of cell
differentiation[38-40]. The expression of c-myc level was reduced
in sodium butyrate-induced differentiation of human hepatoma
cells[41], and in all-trans retinoic acid-induced differentiation
of human leukemic U937 cells with an increase in p21WAF1/CIP1
expression[42]. Our results showed that tachyplesin could increase
the expression of p21WAF1/CIP1 and down-regulate the levels of c-
myc protein in SMMC-7721 cells, and induce the cells to terminal
differentiation as other differentiation inducers[42,43].
      Taken together, the results of the current study indicated
that tachyplesin could effectively inhibit the proliferation of
human hepatoma SMMC-7721 cells, reverse the malignant
morphological and ultrastructural characteristics, alter the
activities of differentiation-associated enzymes and the levels
of tumor-associated antigens, adjust the expression of oncogenes
and tumor suppressor gene correlative with hepatocellular
carcinoma, and so induce hepatocarcinoma cell differentiation.
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